A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
The Battle Against Leukemia and Lymphoma
The Challenges of Patient Recruitment in Oncology Trials - Part 2
This is the second in a 3-part series on ”The Challenges of Patient Recruitment in Oncology Trials”, Senior Patient Recruitment Managers Tricia…
The Center for Immuno-oncology, Cellular, and Gene Therapy Fact Sheet
The Center for Immuno-oncology, Cellular, and Gene Therapy leverages our comprehensive experience and cross-functional experts to build…